Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Early circulating tumor DNA (ctDNA) changes predict survival in mismatch repair or microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC) treated with immune checkpoint ...

Liquid biopsy tests are growing in use and showing promise in cancer detection, but experts say more trials are needed on the clinical benefit of ctDNA testing.

Personalis, Inc. (NASDAQ:PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can accurately identify triple negative breast cancer (TNBC) patients at high risk ...

Guardant Health, Inc. (NASDAQ: GH) and research collaborators have unveiled results from the largest study to date on circulating tumor DNA (ctDNA) testing in stage III colon cancer, presented at ...

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

Lalan Wilfong, MD, of Thyme Care and Texas Oncology, discusses a session on circulating tumor DNA (ctDNA) and shares insight as chair of the Community Oncology Alliance (COA) Payer Reform Committee.

Previous research has shown that people with detectable ctDNA after surgery are at very high risk for recurrence. More than 90% of people with ctDNA will see their cancer return if nothing is done.

The ctDNA results are from over 70 plixorafenib-treated patients and were an exploratory endpoint from a previously completed Phase 1/2a study.

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

A new study reveals blood tests can predict melanoma recurrence by detecting circulating tumor DNA. Research shows 80% of stage 3 melanoma patients with positive tests experience a return of cancer.